Sherwin Sy
About Sherwin Sy
Sherwin Sy is an Associate Director at Nektar Therapeutics, with advanced degrees in Statistics, Pharmacology, and Philosophy. He has extensive experience in the pharmaceutical industry, having held positions at Bristol-Myers Squibb, Thermo Fisher Scientific, and Roche.
Current Role at Nektar Therapeutics
Sherwin Sy serves as the Associate Director at Nektar Therapeutics, a position he has held since 2014. He operates out of South San Francisco, California. In this role, he contributes to the development and implementation of strategies in the pharmaceutical sector, leveraging his extensive background in pharmacology and statistics.
Previous Experience in Pharmaceutical Industry
Prior to his current role, Sherwin Sy held significant positions in the pharmaceutical industry. He worked as a Senior Staff Scientist at Bristol-Myers Squibb from 2000 to 2002 in New Jersey, United States. Following this, he served as a Product Manager at Thermo Fisher Scientific from 2002 to 2009 in Waltham, Massachusetts. Additionally, he was a Clinical Pharmacokinetic Specialist at Roche from 1998 to 2000 in Switzerland.
Educational Background and Expertise
Sherwin Sy has a robust educational background. He earned a Bachelor of Science in Pharmacology from the University of Toronto, followed by a Master of Science in Statistics from Temple University. He also holds a Doctorate in Philosophy from the University of Florida. His academic training supports his expertise in statistical applications within the pharmaceutical field.
Teaching and Mentoring Contributions
In addition to his industry roles, Sherwin Sy has contributed to academia by providing courses on statistical applications in the pharmaceutical setting to graduate students in pharmacy and biostatistics. He has also served as a co-adviser for graduate students, assisting them with their thesis and overall program development.
Research and Methodological Innovations
Sherwin Sy has implemented modeling and simulation strategies in the investigation of phytopharmaceuticals and natural products. He has applied population-based convolution-deconvolution algorithms to study the absorption kinetics of compounds after single-pass in situ perfusion, showcasing his commitment to advancing research methodologies in pharmacology.